📊 BCDA Key Takeaways
Investment Thesis
BioCardia is a pre-revenue or early-stage biotech company burning significant cash with zero revenue generation, indicating failed commercialization or product launch delays. With -$4.9M operating cash flow, -$6.2M net loss, and only $5.3M cash on hand, the company faces a critical runway crisis of approximately 12-14 months at current burn rates. Without immediate revenue generation or successful capital raises, insolvency is a material risk.
BCDA Strengths
- Adequate liquidity ratio of 1.62x suggests short-term bills can be covered
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Cash position of $5.3M provides near-term operational runway
BCDA Risks
- Complete revenue collapse (87.8% YoY decline to $0.00) indicates failed product commercialization or severe market rejection
- Negative operating cash flow of -$4.9M combined with minimal cash reserves creates acute insolvency risk within 12-14 months
- Negative ROE of -237.7% and ROA of -101.6% demonstrate severe value destruction and capital inefficiency
- Operating losses of -$6.3M with no revenue pathway suggests fundamental business model failure
- Gross profit of $107K with zero revenue is unexplained and raises data quality concerns
Key Metrics to Watch
- Cash runway and monthly burn rate trends
- Revenue recognition from any commercial or regulatory approvals
- Capital raise announcements or debt financing activity
- Clinical trial progress and regulatory status updates
BCDA Financial Metrics
💡 AI Analyst Insight
BioCardia, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BCDA Profitability Ratios
BCDA vs Healthcare Sector
How BioCardia, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCDA Balance Sheet & Liquidity
BCDA 5-Year Financial Trend
5-Year Trend Summary: BioCardia, Inc.'s revenue has declined by 33% over the 5-year period, indicating business contraction. The most recent EPS of $-8.19 indicates the company is currently unprofitable.
BCDA Growth Metrics (YoY)
BCDA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.5M | $-0.24 |
| Q2 2025 | N/A | -$1.6M | $-0.40 |
| Q1 2025 | N/A | -$2.3M | $-0.59 |
| Q3 2024 | N/A | -$1.6M | $-0.61 |
| Q2 2024 | $3.0K | -$1.6M | $-0.88 |
| Q1 2024 | $55.0K | -$2.3M | $-0.09 |
| Q3 2023 | $212.0K | -$2.5M | $-0.12 |
| Q2 2023 | $43.0K | -$2.5M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BCDA Capital Allocation
BCDA SEC Filings
Access official SEC EDGAR filings for BioCardia, Inc. (CIK: 0000925741)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCDA
What is the AI rating for BCDA?
BioCardia, Inc. (BCDA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCDA's key strengths?
Adequate liquidity ratio of 1.62x suggests short-term bills can be covered. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk.
What are the risks of investing in BCDA?
Complete revenue collapse (87.8% YoY decline to $0.00) indicates failed product commercialization or severe market rejection. Negative operating cash flow of -$4.9M combined with minimal cash reserves creates acute insolvency risk within 12-14 months.
What is BCDA's revenue and growth?
BioCardia, Inc. reported revenue of $0.0.
Does BCDA pay dividends?
BioCardia, Inc. does not currently pay dividends.
Where can I find BCDA SEC filings?
Official SEC filings for BioCardia, Inc. (CIK: 0000925741) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCDA's EPS?
BioCardia, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.